Investigation Into the Correlation of Plasma Hs-CRP Concentrations and Cardiovascular Risk in Korean Population

Completed

• Conditions: hsCRP

• Registration Number: NCT00819273
• Lead Sponsor: AstraZeneca

Brief Summary

An observational, non-interventional, multi-centre study to provide further information on the utility of test for a predictive marker by investigating the current prevalence of high sensitivity CRP (hs-CRP) testing and characteristics of each CVD risk group.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2009-01-07
• Study First Submitted QC: 2009-01-07
• Study First Posted: 2009-01-08
• Study Start: 2009-03
• Primary Completion: 2009-08
• Study Completion: 2009-08
• Status Verified: 2010-12
• Last Update Submitted: 2010-12-02
• Last Update Posted: 2010-12-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1700

Inclusion Criteria

• Subjects with at least one clinic visit record within the last 12 months from the date of data entry.
• Subjects with at least one hs-CRP level measured within the last 12 months from the date of data entry.

Exclusion Criteria

• Use of statins or other lipid-lowering therapies including fibrates, niacin, and bile acid sequestrants in the past 3 months prior to hsCRP measurement
• Active inflammatory diseases documented during the period of CRP measurement
• Subjects taking immunosuppressants
• Findings of chronic inflammation: arthritis, lupus, or inflammatory bowel disease

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluate hs-CRP levels according to risk categories by the NCEP ATP III.	Within the last 12 months from the date of data entry.

Secondary Outcome Measures

Name	Time	Method
Evaluate a relationship between hs-CRP and each CHD CVD risk factor including LDL-C.	Within the last 12 months from the date of data entry.

Trial Locations

Locations (1)

Research Site; 🇰🇷 Seoul, Korea, Republic of